

Massimo Breccia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7737933/massimo-breccia-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

682
papers

10,631
citations

48
h-index

81
g-index

727
ext. papers

12,485
ext. citations

3.8
avg, IF

6.16
L-index

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 682 | Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients.. <i>Supportive Care in Cancer</i> , 2022 , 30, 4303 | 3.9 | 1 |
| 681 | Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments.. <i>Advances in Therapy</i> , 2022 , 39, 1101 | 4.1 | |
| 680 | Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.. <i>British Journal of Haematology</i> , 2022 , | 4.5 | 2 |
| 679 | Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform.. <i>Frontiers in Oncology</i> , 2022 , 12, 826040 | 5.3 | 1 |
| 678 | Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 839915 | 5.3 | 0 |
| 677 | Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.. <i>Annals of Hematology</i> , 2022 , 1 | 3 | 1 |
| 676 | Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.. <i>International Journal of Hematology</i> , 2022 , 1 | 2.3 | 1 |
| 675 | Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021 , 138, 3603-3603 | 2.2 | 0 |
| 674 | Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021 , 138, 1487-1487 | 2.2 | |
| 673 | Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021 , 138, 3617-3617 | 2.2 | |
| 672 | Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021 , 138, 1283-1283 | 2.2 | 0 |
| 671 | Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 1486-1486 | 2.2 | |
| 670 | Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. <i>Blood</i> , 2021 , 138, 4017-4017 | 2.2 | 0 |
| 669 | Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021 , 138, 2581-2581 | 2.2 | 1 |
| 668 | Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy. <i>Blood</i> , 2021 , 138, 1943-1943 | 2.2 | |
| 667 | First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021 , 138, 1474-1474 | 2.2 | 1 |
| 666 | COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2021 , 196, 559 | 4.5 | 5 |

| | | | |
|-----|---|------|---|
| 665 | Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplitmab. <i>Annals of Hematology</i> , 2021 , 100, 2117-2119 | 3 | 2 |
| 664 | Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021 , 39, 409-418 | 1.3 | 3 |
| 663 | Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2021 , 14, 293-302 | 2.8 | 1 |
| 662 | Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 631570 | 5.3 | 0 |
| 661 | American Society of Hematology 2020 Podcast Collection: CML. <i>Advances in Therapy</i> , 2021 , 38, 26-30 | 4.1 | |
| 660 | American Society of Hematology 2020 Podcast Collection: MPN. <i>Advances in Therapy</i> , 2021 , 38, 16-19 | 4.1 | |
| 659 | Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2261-2266 | 1.9 | |
| 658 | Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. <i>Hematological Oncology</i> , 2021 , 39, 401-408 | 1.3 | 1 |
| 657 | Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021 , 100, 1213-1219 | 3 | 2 |
| 656 | Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , 2021 , 11, 642005 | 5.3 | 4 |
| 655 | New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2280-2283 | 1.9 | 2 |
| 654 | Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021 , 127, 2657-2665 | 6.4 | 7 |
| 653 | Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021 , 35, 1814-1816 | 10.7 | 0 |
| 652 | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021 , 11, 638689 | 5.3 | |
| 651 | The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2021 , 10, e25271 | 2 | 2 |
| 650 | Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 803-811 | 5.9 | 5 |
| 649 | Measuring prognosis in chronic myeloid leukemia: what's new?. <i>Expert Review of Hematology</i> , 2021 , 14, 577-585 | 2.8 | |
| 648 | Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. <i>Blood Reviews</i> , 2021 , 45, 100689 | 11.1 | 9 |

| | | | |
|-----|---|-----|----|
| 647 | Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1022-1025 | 1.9 | 1 |
| 646 | Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e328-e333 | 2 | |
| 645 | Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 669-678 | 1.9 | 3 |
| 644 | Smoothered inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 739-742 | 1.9 | 2 |
| 643 | Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. <i>British Journal of Haematology</i> , 2021 , 193, 129-132 | 4.5 | 7 |
| 642 | Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103163 | 7 | 5 |
| 641 | Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021 , 193, 356-368 | 4.5 | 8 |
| 640 | Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2021 , 192, 237-238 | 4.5 | |
| 639 | Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2021 , 24, 887-893 | 2.2 | 1 |
| 638 | Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1026-1027 | 1.9 | 2 |
| 637 | Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13356 | 4.6 | 3 |
| 636 | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021 , 11, 4 | 7 | 16 |
| 635 | Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 4 |
| 634 | Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. <i>Expert Review of Hematology</i> , 2021 , 14, 645-654 | 2.8 | 1 |
| 633 | Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021 , 11, 739171 | 5.3 | 1 |
| 632 | Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021 , 60, 1520-1526 | 3.2 | 0 |
| 631 | Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). <i>Leukemia and Lymphoma</i> , 2021 , 1-10 | 1.9 | 0 |
| 630 | Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. <i>Cancers</i> , 2021 , 13, | 6.6 | 4 |

| | | | |
|-----|---|------|----|
| 629 | The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021 , 137, 31-44 | 5.7 | 3 |
| 628 | Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021 , 5, 4370-4379 | 7.8 | 1 |
| 627 | Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021 , 60, 1527-1533 | 3.2 | 0 |
| 626 | Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , 2021 , 100, 481-485 | 3 | 4 |
| 625 | Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021 , 100, 2005-2014 | 3 | 3 |
| 624 | Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients.. <i>Expert Review of Hematology</i> , 2021 , 1-8 | 2.8 | 0 |
| 623 | Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020 , 105, 286-291 | 3.8 | 1 |
| 622 | Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020 , 34, 1495-1502 | 10.7 | 34 |
| 621 | Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020 , 99, 2773-2777 | 3 | 1 |
| 620 | Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020 , 99, 1525-1530 | 3 | 4 |
| 619 | Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020 , 10, 66 | 7 | 1 |
| 618 | Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020 , 10, 883 | 5.3 | 11 |
| 617 | Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. <i>American Journal of Hematology</i> , 2020 , 95, E260-E263 | 7.1 | 7 |
| 616 | Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020 , 34, 2260-2261 | 10.7 | 37 |
| 615 | Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. <i>Annals of Hematology</i> , 2020 , 99, 65-72 | 3 | 5 |
| 614 | High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020 , 112, 141-146 | 2.3 | 0 |
| 613 | Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020 , 190, e304-e307 | 4.5 | 1 |
| 612 | Direct oral anticoagulants in patients with hematologic malignancies. <i>Hematological Oncology</i> , 2020 , 38, 589-596 | 1.3 | 4 |

| | | | |
|-----|---|------|----|
| 611 | Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached. <i>EclinicalMedicine</i> , 2020 , 19, 100277 | 11.3 | 0 |
| 610 | The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020 , 34, 2451-2459 | 10.7 | 9 |
| 609 | First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure". <i>Lancet Haematology,the</i> , 2020 , 7, e182-e183 | 14.6 | |
| 608 | Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020 , 38, 372-380 | 1.3 | 7 |
| 607 | Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1199-1209 | 3.6 | 7 |
| 606 | How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). <i>Cancer Medicine</i> , 2020 , 9, 4160-4165 | 4.8 | 11 |
| 605 | Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020 , 136, 47-48 | 2.2 | |
| 604 | Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020 , 136, 17-18 | 2.2 | 0 |
| 603 | Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020 , 136, 45-46 | 2.2 | |
| 602 | Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020 , 136, 8-9 | 2.2 | |
| 601 | Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020 , 136, 49-50 | 2.2 | |
| 600 | Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION. <i>Blood</i> , 2020 , 136, 31-32 | 2.2 | 0 |
| 599 | First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020 , 136, 43-44 | 2.2 | |
| 598 | Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". <i>European Journal of Haematology</i> , 2020 , 105, 335-343 | 3.8 | 1 |
| 597 | Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020 , | 2.2 | 1 |
| 596 | Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". <i>Blood</i> , 2020 , 136, 35-36 | 2.2 | 1 |
| 595 | Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. <i>Blood</i> , 2020 , 136, 47-50 | 2.2 | 13 |
| 594 | Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020 , 136, 43-44 | 2.2 | 2 |

| | | | |
|-----|--|------|----|
| 593 | Prognostic Significance of Transcript-Type in Chronic Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020 , 12, e2020062 | 3.2 | 3 |
| 592 | Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020 , 34, 488-498 | 10.7 | 20 |
| 591 | Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. <i>Haematologica</i> , 2020 , 105, 1559-1566 | 6.6 | 14 |
| 590 | Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020 , 126, 1243-1252 | 6.4 | 51 |
| 589 | The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020 , 61, 536-545 | 1.9 | 3 |
| 588 | Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020 , 38, 189-196 | 1.3 | 1 |
| 587 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020 , 34, 2805-2808 | 10.7 | 10 |
| 586 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 2 |
| 585 | Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020 , 38, 607-610 | 1.3 | 1 |
| 584 | Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Clinical Drug Investigation</i> , 2020 , 40, 1177-1187 | 3.2 | 2 |
| 583 | Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3476-3483 | 1.9 | 0 |
| 582 | The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020 , 13, 1067-1072 | 2.8 | 1 |
| 581 | On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 1075-1081 | 3.5 | 3 |
| 580 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020 , 34, 2813-2814 | 10.7 | 11 |
| 579 | A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2020 , 95, E329-E332 | 7.1 | 11 |
| 578 | Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020 , 99, 2405-2416 | 3 | 3 |
| 577 | Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020 , 13, 1311-1318 | 2.8 | 3 |
| 576 | The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <i>Bone Marrow Transplantation</i> , 2020 , 55, 708-716 | 4.4 | 11 |

| | | | |
|-----|--|------|----|
| 575 | Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020 , 301, 163-166 | 3.2 | 13 |
| 574 | Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020 , 34, 914-918 | 10.7 | 26 |
| 573 | Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S287-S288 | 2 | 2 |
| 572 | Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019 , 98, 1933-1936 | 3 | 2 |
| 571 | Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019 , 98, 1919-1925 | 3 | 8 |
| 570 | Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019 , 94, E239-E242 | 7.1 | 3 |
| 569 | Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019 , 98, 1891-1904 | 3 | 7 |
| 568 | Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019 , 37, 291-295 | 1.3 | 10 |
| 567 | Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019 , 98, 1885-1890 | 3 | 10 |
| 566 | Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019 , 288, 124-127 | 3.2 | 13 |
| 565 | Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019 , 81, 25-26 | 2.7 | 2 |
| 564 | Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019 , 37, 418-423 | 1.3 | 2 |
| 563 | Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019 , 37, 296-302 | 1.3 | 33 |
| 562 | Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019 , 104, 1589-1596 | 6.6 | 38 |
| 561 | Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719826444 | 5.7 | 13 |
| 560 | Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019 , 98, 2329-2338 | 3 | 9 |
| 559 | Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019 , 94, 1254-1265 | 7.1 | 24 |
| 558 | Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019025 | 3.2 | 5 |

| | | | |
|-----|---|-----|----|
| 557 | Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019 , 37, 652-654 | 1.3 | 10 |
| 556 | Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S290-S291 | 2 | 3 |
| 555 | Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019 , 42, 660-664 | 2.8 | 0 |
| 554 | A journey through infectious risk associated with ruxolitinib. <i>British Journal of Haematology</i> , 2019 , 187, 286-295 | 4.5 | 21 |
| 553 | Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019 , 134, 1652-1652 | 2.2 | 2 |
| 552 | Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019 , 134, 4145-4145 | 2.2 | 2 |
| 551 | Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kinase Inhibitors. <i>Blood</i> , 2019 , 134, 1649-1649 | 2.2 | 4 |
| 550 | Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019 , 134, 839-839 | 2.2 | 2 |
| 549 | Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18220-e18220 | 2.2 | |
| 548 | Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e23073-e23073 | 2.2 | |
| 547 | Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019 , 134, 4166-4166 | 2.2 | |
| 546 | Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019 , 134, 4188-4188 | 2.2 | |
| 545 | Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019 , 134, 3010-3010 | 2.2 | |
| 544 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019 , 134, 4153-4153 | 2.2 | |
| 543 | Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4184-4184 | 2.2 | |
| 542 | Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4174-4174 | 2.2 | 1 |
| 541 | Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. <i>Blood</i> , 2019 , 134, 4179-4179 | 2.2 | |
| 540 | Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019 , 134, 3845-3845 | 2.2 | 1 |

| | | | |
|-----|--|------|-----|
| 539 | Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial. <i>Blood</i> , 2019 , 134, 4155-4155 | 2.2 | 0 |
| 538 | Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019 , 3, 4280-4290 | 7.8 | 40 |
| 537 | Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 131 | 22.4 | 19 |
| 536 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019 , 381, 2315-2326 | 59.2 | 114 |
| 535 | Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019 , 33, 1598-1607 | 10.7 | 8 |
| 534 | Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. <i>Leukemia Research</i> , 2019 , 76, 65-69 | 2.7 | 3 |
| 533 | Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019 , 12, 81-87 | 2.8 | 7 |
| 532 | Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019 , 98, 889-896 | 3 | 4 |
| 531 | Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2019 , 17, 686-696 | 0.6 | 4 |
| 530 | Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018 , 20, 23 | 6.3 | 15 |
| 529 | Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018 , 97, 745-754 | 3 | 6 |
| 528 | Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project. <i>Quality of Life Research</i> , 2018 , 27, 1545-1554 | 3.7 | 5 |
| 527 | Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018 , 124, 2228-2237 | 6.4 | 20 |
| 526 | Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018 , 97, 1577-1580 | 3 | 25 |
| 525 | Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018 , 36, 561 | 1.3 | 38 |
| 524 | Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018 , 69, 18-23 | 2.7 | 2 |
| 523 | Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018 , 93, E159-E161 | 7.1 | 19 |
| 522 | Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option. <i>Clinical Drug Investigation</i> , 2018 , 38, 475-476 | 3.2 | 15 |

521 Special Situations in APL **2018**, 203-210

520 Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. *Expert Review of Hematology*, **2018**, 11, 301-306 2.8 8

519 Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. *British Journal of Haematology*, **2018**, 181, 275-278 4.5 2

518 Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. *British Journal of Haematology*, **2018**, 181, 267-270 4.5 7

517 Comparison of JAK2 -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. *Hematological Oncology*, **2018**, 36, 269-275 1.3 6

516 Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematological Oncology*, **2018**, 36, 285-290 1.3 19

515 Association between proteomic profile and molecular response in chronic myeloid leukemia patients. *Leukemia and Lymphoma*, **2018**, 59, 1016-1018 1.9

514 Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Annals of Hematology*, **2018**, 97, 95-100 3 14

513 Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. *Annals of Hematology*, **2018**, 97, 1797-1802 3 14

512 Residual Peripheral Blood CD26 Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. *Frontiers in Oncology*, **2018**, 8, 194 5.3 56

511 Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. *British Journal of Haematology*, **2018**, 183, 35-46 4.5 6

510 Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. *Leukemia Research*, **2018**, 71, 89-91 2.7 0

509 Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. *Seminars in Hematology*, **2018**, 55, 248-255 4 13

508 Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. *European Journal of Haematology*, **2018**, 101, 578 3.8 2

507 Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. *Annals of Hematology*, **2018**, 97, 1767-1774 3 9

506 Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. *Blood*, **2018**, 132, 2293-2293¹ 2.2 2293¹

505 Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. *Blood*, **2018**, 132, 3006-3006 2.2 1

504 Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. *Blood*, **2018**, 132, 792-792 2.2 5

| | | | |
|-----|---|-----|----|
| 503 | Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018 , 132, 4277-4277 | 2.2 | 8 |
| 502 | Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018 , 132, 45-45 | 2.2 | 2 |
| 501 | One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018 , 132, 1732-1732 | 2.2 | 1 |
| 500 | The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018 , 132, 44-44 | 2.2 | 6 |
| 499 | International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018 , 132, 1750-1750 | 2.2 | 3 |
| 498 | Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018 , 132, 458-458 | 2.2 | 2 |
| 497 | Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018 , 9, 7534-7540 | 3.3 | 10 |
| 496 | Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018 , 9, 21758-21769 | 3.3 | 2 |
| 495 | Ponatinib: A Review of Efficacy and Safety. <i>Current Cancer Drug Targets</i> , 2018 , 18, 847-856 | 2.8 | 26 |
| 494 | Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7081-TPS7081 | 2.2 | 1 |
| 493 | Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018 , 132, 1746-1746 | 2.2 | |
| 492 | Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018 , 132, 3052-3052 | 2.2 | |
| 491 | Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018 , 132, 5518-5518 | 2.2 | |
| 490 | Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018 , 132, 1741-1741 | 2.2 | |
| 489 | Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018 , 132, 5516-5516 | 2.2 | |
| 488 | Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018 , 132, 5438-5438 | 2.2 | |
| 487 | Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018 , 132, 4312-4312 | 2.2 | |
| 486 | Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018 , 132, 5471-5471 | 2.2 | |

| | | | |
|-----|--|------|----|
| 485 | Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018 , 132, 3021-3021 | 2.2 | |
| 484 | Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018 , 132, 5464-5464 | 2.2 | |
| 483 | Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018 , 124, 1251-1259 | 6.4 | 21 |
| 482 | Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018 , 182, 427-429 | 4.5 | 5 |
| 481 | Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018 , 74, 86-88 | 2.7 | 14 |
| 480 | Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018 , 97, 1803-1808 | 3 | 8 |
| 479 | Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 623-628 | 4.1 | 8 |
| 478 | Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017 , 35, 232-236 | 1.3 | 11 |
| 477 | Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017 , 177, 741-750 | 4.5 | 16 |
| 476 | The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017 , 92, 797-805 | 7.1 | 52 |
| 475 | Second line small molecule therapy options for treating chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 57-65 | 4 | 7 |
| 474 | Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 1530-1536 | 6.6 | 12 |
| 473 | Are chronic myeloid leukemia patients ready to stop long-term treatment?. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2976-2978 | 1.9 | 1 |
| 472 | Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. <i>Cancer Medicine</i> , 2017 , 6, 1233-1239 | 4.8 | 6 |
| 471 | A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≥30% blasts. <i>Leukemia</i> , 2017 , 31, 2799-2806 | 10.7 | 44 |
| 470 | How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. <i>Expert Review of Hematology</i> , 2017 , 10, 155-159 | 2.8 | 6 |
| 469 | Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017 , 92, E668-E670 | 7.1 | 4 |
| 468 | Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 204 | 3 | |

| | | | |
|-----|--|-----|-----|
| 467 | Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 1001-1008 | 3.8 | 10 |
| 466 | The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, E661-E664 | 7.1 | 11 |
| 465 | High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. <i>Thrombosis Research</i> , 2017 , 156, 168-171 | 8.2 | 7 |
| 464 | Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017 , 96, 549-558 | 3 | 32 |
| 463 | Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017 , 92, 37-41 | 7.1 | 53 |
| 462 | Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 605-612 | 2.2 | 220 |
| 461 | Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017 , 35, 804-809 | 1.3 | 5 |
| 460 | Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017 , 96, 387-391 | 3 | 11 |
| 459 | Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086 | 3.3 | 38 |
| 458 | A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017046 | 3.2 | 2 |
| 457 | Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016 , 101, e267-8 | 6.6 | 7 |
| 456 | Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. <i>Supportive Care in Cancer</i> , 2016 , 24, 4887-4894 | 3.9 | 13 |
| 455 | Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. <i>Leukemia Research</i> , 2016 , 48, 20-5 | 2.7 | 9 |
| 454 | Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 107, 190-198 | 7 | 14 |
| 453 | Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016 , 101, 1200-1207 | 6.6 | 19 |
| 452 | Current standard treatment of adult acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016 , 172, 841-54 | 4.5 | 50 |
| 451 | Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. <i>Supportive Care in Cancer</i> , 2016 , 24, 4487-93 | 3.9 | 8 |
| 450 | How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1517-26 | 4 | 1 |

| | | | |
|-----|--|-----|----|
| 449 | Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016 , 91, 318-21 | 7.1 | 19 |
| 448 | Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016 , 57, 99-102 | 1.9 | 11 |
| 447 | Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 525-33 | 4.1 | 8 |
| 446 | The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016 , 95, 211-9 | 3 | 13 |
| 445 | Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 376-88 | 7 | 10 |
| 444 | Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016 , 40, 24-9 | 2.7 | 4 |
| 443 | Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016 , 128, 1128-1128 | 2.2 | 4 |
| 442 | Incidence of Severe ($\geq 10g/dl$) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. <i>Blood</i> , 2016 , 128, 1903-1903 ^{2,2} | | 0 |
| 441 | Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016 , 128, 1951-1951 | 2.2 | 2 |
| 440 | Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. <i>Blood</i> , 2016 , 128, 2415-2415 | 2.2 | 1 |
| 439 | Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. <i>Blood</i> , 2016 , 128, 3068-3068 | 2.2 | 1 |
| 438 | Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016 , 128, 3070-3070 | 2.2 | 7 |
| 437 | Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016 , 128, 4251-4251 | 2.2 | 2 |
| 436 | Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. <i>Blood</i> , 2016 , 128, 448-448 | 2.2 | 3 |
| 435 | Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , 2016 , 128, 625-625 | 2.2 | 12 |
| 434 | Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016 , 128, 942-942 | 2.2 | 2 |
| 433 | Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016 , 7, 80083-80090 | 3.3 | 21 |
| 432 | The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016 , 128, 3097-3097 | 2.2 | |

| | | | |
|-----|--|------|-----|
| 431 | Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2016 , 128, 5939-5939 | 2.2 | |
| 430 | Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 1242-1242 | 2.2 | |
| 429 | Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016 , 128, 5464-5464 | 2.2 | |
| 428 | Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016 , 128, 5473-5473 | 2.2 | |
| 427 | Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016 , 128, 5544-5544 | 2.2 | 1 |
| 426 | Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016 , 128, 5469-5469 | 2.2 | |
| 425 | Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016 , 128, 5465-5465 | 2.2 | |
| 424 | Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016 , 128, 3078-3078 | 2.2 | |
| 423 | Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016 , 96, 643-9 | 3.8 | 17 |
| 422 | Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 617-22 | 7.1 | 10 |
| 421 | Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016 , 96, 344-51 | 3.8 | 24 |
| 420 | Current first- and second-line treatment options in acute promyelocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2016 , 5, 105-118 | 1 | 5 |
| 419 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. <i>Leukemia</i> , 2016 , 30, 1648-71 | 10.7 | 283 |
| 418 | PML-RAR β kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016 , 30, 1987-1992 | 10.7 | 57 |
| 417 | Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1453-4 | 2.5 | 2 |
| 416 | Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. <i>Annals of Hematology</i> , 2016 , 95, 1059-65 | 3 | 6 |
| 415 | Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016 , 18, 536-40 | 6.4 | 16 |
| 414 | Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2016 , 173, 945-6 | 4.5 | 5 |

| | | | |
|-----|---|------|----|
| 413 | Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016 , 174, 160-2 | 4.5 | 6 |
| 412 | Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015 , 90, E95-6 | 7.1 | |
| 411 | Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. <i>Leukemia Research</i> , 2015 , 39, 1028-33 | 2.7 | 16 |
| 410 | An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015 , 94, 771-7 | 3 | 22 |
| 409 | Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015 , 95, 52-6 | 3.8 | 19 |
| 408 | Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015 , 29, 1084-91 | 10.7 | 53 |
| 407 | The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Acta Haematologica</i> , 2015 , 134, 57-8 | 2.7 | |
| 406 | Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015 , 29, 1344-9 | 10.7 | 48 |
| 405 | Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015 , 100, 1146-50 | 6.6 | 29 |
| 404 | Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015 , 5, e347 | 7 | 22 |
| 403 | Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015 , 29, 1823-31 | 10.7 | 64 |
| 402 | Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline. <i>British Journal of Haematology</i> , 2015 , 169, 148-50 | 4.5 | 5 |
| 401 | Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , 2015 , 16, 1506-1514 | 21.7 | 60 |
| 400 | Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015 , 39, 1055-9 | 2.7 | 43 |
| 399 | Bosutinib for Chronic Myeloid Leukemia. <i>Rare Cancers and Therapy</i> , 2015 , 3, 35-46 | | 2 |
| 398 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. <i>Rare Cancers and Therapy</i> , 2015 , 3, 119-132 | | 5 |
| 397 | Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015 , 39, 859-65 | 2.7 | 12 |
| 396 | Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. <i>Annals of Hematology</i> , 2015 , 94, 393-7 | 3 | 47 |

| | | | |
|-----|---|------|----|
| 395 | Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes. <i>Journal of Diabetes</i> , 2015 , 7, 493-6 | 3.8 | |
| 394 | Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015 , 168, 361-70 | 4.5 | 40 |
| 393 | Ponatinib in chronic myeloid leukaemia: ready for first-line?. <i>Lancet Haematology</i> , 2015 , 2, e352-3 | 14.6 | |
| 392 | Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015 , 90, 105-8 | 7.1 | 8 |
| 391 | Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. <i>Clinical Investigation</i> , 2015 , 5, 257-265 | | 1 |
| 390 | Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015 , 90, E181-2 | 7.1 | 2 |
| 389 | Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015 , 33, 48-51 | 1.3 | 2 |
| 388 | Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. <i>American Journal of Hematology</i> , 2015 , 90, E100-1 | 7.1 | 12 |
| 387 | Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015 , 23, 3289-95 | 3.9 | 31 |
| 386 | Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2206-7 | 1.9 | 5 |
| 385 | Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015 , 94, 195-200 | 3 | 12 |
| 384 | Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015 , 90, E80-5 | 7.1 | 59 |
| 383 | Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015 , 39, 314-7 | 2.7 | 10 |
| 382 | Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192 | 10.3 | 48 |
| 381 | Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015 , 126, 1606-1606 | 2.2 | 2 |
| 380 | Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015 , 126, 2792-2792 | 2.2 | 0 |
| 379 | Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. <i>Blood</i> , 2015 , 126, 2799-2799 | 2.2 | 5 |
| 378 | Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. <i>Blood</i> , 2015 , 126, 4038-4038 | 2.2 | 1 |

| | | | |
|-----|---|-----|----|
| 377 | Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015 , 126, 2099-2099 | 2.2 | |
| 376 | JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015 , 126, 1614-1614 | 2.2 | |
| 375 | Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015 , 126, 1570-1570 | 2.2 | |
| 374 | The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015 , 126, 2815-2815 | 2.2 | |
| 373 | Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015 , 126, 1582-1582 | 2.2 | |
| 372 | Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015 , 126, 4046-4046 | 2.2 | |
| 371 | Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. <i>Blood</i> , 2015 , 126, 2811-2811 | 2.2 | |
| 370 | Application of the International Prognostic Score of Thrombosis for Essential Thrombocythemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. <i>Blood</i> , 2015 , 126, 2821-2821 | 2.2 | |
| 369 | Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015 , 126, 1598-1598 | 2.2 | |
| 368 | Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). <i>BioDrugs</i> , 2014 , 28, 17-26 | 7.9 | 21 |
| 367 | Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. <i>Cancer Letters</i> , 2014 , 347, 22-8 | 9.9 | 16 |
| 366 | Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014 , 93, 1413-20 | 3 | 3 |
| 365 | Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014 , 89, 565 | 7.1 | 2 |
| 364 | Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014 , 89, 119-24 | 7.1 | 12 |
| 363 | Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014 , 89, 542-6 | 7.1 | 24 |
| 362 | Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3406-12 | 2.2 | 61 |
| 361 | Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014 , 38, 1173-6 | 2.7 | 22 |
| 360 | Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. <i>Annals of Hematology</i> , 2014 , 93, 1951-2 | 3 | 22 |

| | | | |
|-----|---|------|----|
| 359 | Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014 , 93, 1819-23 | 3 | 15 |
| 358 | International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. <i>Quality of Life Research</i> , 2014 , 23, 825-36 | 3.7 | 52 |
| 357 | Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014 , 167, 428-30 | 4.5 | 3 |
| 356 | Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014 , 38, 194-7 | 2.7 | 17 |
| 355 | Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 181-9 | 7 | 4 |
| 354 | Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S112-6 | 8.2 | 37 |
| 353 | Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> . 2013;121(26):5138-5144.. <i>Blood</i> , 2014 , 123, 2902-2902 | 2.2 | 78 |
| 352 | Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014011 | 3.2 | 9 |
| 351 | Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia and Lymphoma</i> , 2014 , 55, 204-6 | 1.9 | 1 |
| 350 | Patient-reported outcomes in acute leukemia: a roadmap for future research. <i>European Journal of Haematology</i> , 2014 , 93, 86-7 | 3.8 | 1 |
| 349 | How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. <i>Leukemia Research</i> , 2014 , 38, 1392-8 | 2.7 | 33 |
| 348 | Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1621-30 | 4 | 3 |
| 347 | ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?. <i>Current Opinion in Hematology</i> , 2014 , 21, 95-101 | 3.3 | 7 |
| 346 | Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014003 | 3.2 | 16 |
| 345 | Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014 , 25, 447-54 | 10.3 | 31 |
| 344 | Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2014 , 38, 294-8 | 2.7 | 27 |
| 343 | Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia. <i>International Journal of Hematology</i> , 2014 , 99, 100-1 | 2.3 | |
| 342 | Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia [Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014 , 124, 12-12 | 2.2 | 5 |

| | | | |
|-----|--|------|-----|
| 341 | Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. <i>Blood Transfusion</i> , 2014 , 12 Suppl 1, s162-3 | 3.6 | 3 |
| 340 | Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. <i>Blood</i> , 2014 , 124, 1855-1855 | 2.2 | |
| 339 | Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. <i>Blood</i> , 2014 , 124, 4532-4532 | 2.2 | |
| 338 | Real-life Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 5530-5530 | 2.2 | |
| 337 | Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. <i>Blood</i> , 2014 , 124, 1794-1794 | 2.2 | 1 |
| 336 | Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 3687-3687 | 2.2 | |
| 335 | Systematic Coronary Risk Evaluation (SCORE) Chart Identify Chronic Myeloid Leukemia Patients at Risk of Cardiovascular Diseases during Nilotinib Treatment. <i>Blood</i> , 2014 , 124, 4545-4545 | 2.2 | |
| 334 | Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014 , 124, 3265-3265 | 2.2 | |
| 333 | Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 1063-1063 | 2.2 | |
| 332 | Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. <i>Blood</i> , 2014 , 124, 3141-3141 | 2.2 | |
| 331 | Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014 , 124, 5326-5326 | 2.2 | |
| 330 | Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2014 , 124, 3189-3189 | 2.2 | |
| 329 | Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013 , 31, 103-9 | 1.3 | 44 |
| 328 | Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , 2013 , 369, 111-21 | 59.2 | 964 |
| 327 | Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. <i>Drugs and Aging</i> , 2013 , 30, 629-37 | 4.7 | 29 |
| 326 | Management options for refractory chronic myeloid leukemia: considerations for the elderly. <i>Drugs and Aging</i> , 2013 , 30, 467-77 | 4.7 | 3 |
| 325 | Imatinib induces body mass changes in women with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 1581-2 | 3 | 4 |
| 324 | Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. <i>Annals of Hematology</i> , 2013 , 92, 1413-4 | 3 | 3 |

| | | | |
|-----|---|------|----|
| 323 | Efficacy and safety of deferasirox in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2013 , 92, 863-70; | | 25 |
| 322 | Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 179-83 | 3 | 8 |
| 321 | Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013 , 92, 25-32 | 3 | 20 |
| 320 | Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1786-7 | 1.9 | 7 |
| 319 | Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. <i>Annals of Hematology</i> , 2013 , 92, 411-2 | 3 | 12 |
| 318 | Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?. <i>Leukemia Research</i> , 2013 , 37, 204-5 | 2.7 | 5 |
| 317 | Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2458-65 | 1.9 | 22 |
| 316 | Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013 , 333, 32-5 | 9.9 | 13 |
| 315 | Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2013 , 37, 713-20 | 2.7 | 26 |
| 314 | Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 90, 345-8 | 3.8 | 35 |
| 313 | Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013 , 37, 383-5 | 2.7 | 3 |
| 312 | The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 669-70 ^{1.9} | | 1 |
| 311 | High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 658-61 | 1.9 | 45 |
| 310 | Management of acute promyelocytic leukemia in the elderly. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013045 | 3.2 | 5 |
| 309 | Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. <i>Acta Haematologica</i> , 2013 , 129, 126-34 ^{2.7} | | 5 |
| 308 | Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. <i>Leukemia and Lymphoma</i> , 2013 , 54, 411-2 | 1.9 | 3 |
| 307 | Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013 , 27, 1511-9 | 10.7 | 94 |
| 306 | Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2671-7 | 2.2 | 97 |

| | | | |
|-----|--|-----|-----|
| 305 | Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013 , 121, 5138-44 | 2.2 | 36 |
| 304 | The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013 , 121, 4439-42 | 2.2 | 444 |
| 303 | Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013 , 98, 399-403 | 6.6 | 28 |
| 302 | FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013 , 98, e161-3 | 6.6 | 37 |
| 301 | Systematic review of dasatinib in chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2013 , 6, 257-65 | 4.4 | 10 |
| 300 | Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , 2013 , 122, 1406-1406 | 2.2 | 1 |
| 299 | Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013 , 122, 258-258 | 2.2 | 2 |
| 298 | Exclusion Criteria In The Dasison and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a Real-life Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013 , 122, 4002-4002 | 2.2 | 0 |
| 297 | Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013 , 122, 770-770 | 2.2 | 2 |
| 296 | Current targeted therapy with tyrosine kinase inhibitors 2013 , 50-61 | | |
| 295 | The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013 , 122, 1486-1486 | 2.2 | |
| 294 | 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013 , 122, 4000-4000 | 2.2 | |
| 293 | FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013 , 122, 1336-1336 | 2.2 | |
| 292 | Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013 , 122, 2659-2659 | 2.2 | |
| 291 | Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013 , 122, 5229-5229 | 2.2 | |
| 290 | Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013 , 122, 1594-1594 | 2.2 | |
| 289 | Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. <i>Blood</i> , 2013 , 122, 5203-5203 | 2.2 | |
| 288 | Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 123-35 | 7 | 23 |

| | | | |
|-----|---|------|----|
| 287 | Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. <i>Leukemia Research</i> , 2012 , 36, e66-7 | 2.7 | 21 |
| 286 | Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2012 , 36, 546-7 | 2.7 | 1 |
| 285 | Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies. <i>Leukemia Research</i> , 2012 , 36, 682-3 | 2.7 | 1 |
| 284 | Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?. <i>Leukemia Research</i> , 2012 , 36, 813-4 | 2.7 | 7 |
| 283 | Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. <i>Cancer</i> , 2012 , 118, 404-9 | 6.4 | 30 |
| 282 | Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012 , 91, 309-10 | 3 | 2 |
| 281 | MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. <i>Haematologica</i> , 2012 , 97, e2 | 6.6 | 19 |
| 280 | Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges. <i>Cancer Letters</i> , 2012 , 325, 18-25 | 9.9 | 1 |
| 279 | Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2073-4 | 1.9 | |
| 278 | Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. <i>British Journal of Cancer</i> , 2012 , 107, 904-9 | 8.7 | 81 |
| 277 | Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. <i>Annals of Hematology</i> , 2012 , 91, 1371-81 | 3 | 39 |
| 276 | How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. <i>Cancer Letters</i> , 2012 , 322, 127-32 | 9.9 | 13 |
| 275 | Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 44 | 22.4 | 37 |
| 274 | Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012 , 159, 612-3 | 4.5 | 6 |
| 273 | The EUTOS score identifies chronic myeloid leukaemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012 , 36, e209-10 | 2.7 | 17 |
| 272 | Prognostic features of patients with myelodysplastic syndromes aged Leukemia and Lymphoma, 2012 , 53, 2439-43 | 1.9 | 6 |
| 271 | Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1031-43 | 4 | 42 |
| 270 | Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR γ rearrangement and type 1 diabetes. <i>Annals of Hematology</i> , 2012 , 91, 1823-4 | 3 | 12 |

| | | | |
|-----|---|-----|----|
| 269 | Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 497-8 | 1.9 | 5 |
| 268 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012 , 91, 1345-9 | 3 | 28 |
| 267 | Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84, 93-100 | 7 | 23 |
| 266 | Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012 , 118, 5265-9 | 6.4 | 13 |
| 265 | 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1558-60 | 1.9 | 12 |
| 264 | Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012 , 119, 49-54 | 2.2 | 52 |
| 263 | Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. <i>Haematologica</i> , 2012 , 97, 1731-5 | 6.6 | 18 |
| 262 | Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. <i>Leukemia and Lymphoma</i> , 2012 , 53, 985-6 | 1.9 | 19 |
| 261 | Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012 , 97, 560-7 | 6.6 | 54 |
| 260 | Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Current Cancer Drug Targets</i> , 2012 , 12, 391-401 | 2.8 | 3 |
| 259 | The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. <i>Blood</i> , 2012 , 120, 1678-1678 | 2.2 | 0 |
| 258 | The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2012 , 120, 1680-1680 | 2.2 | 4 |
| 257 | Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , 2012 , 120, 1686-1686 | 2.2 | 10 |
| 256 | Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. <i>Blood</i> , 2012 , 120, 3784-3784 | 2.2 | 4 |
| 255 | ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , 2012 , 120, 6-6 | 2.2 | 12 |
| 254 | The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. <i>Blood</i> , 2012 , 120, 5062-5062 | 2.2 | |
| 253 | Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. <i>Blood</i> , 2012 , 120, 4958-4958 | 2.2 | |
| 252 | Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. <i>Blood</i> , 2012 , 120, 4951-4951 | 2.2 | |

| | | | |
|-----|--|-----|-----|
| 251 | Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.. <i>Blood</i> , 2012 , 120, 2784-2784 | 2.2 | |
| 250 | Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012 , 120, 3163-3163 | 2.2 | |
| 249 | Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. <i>Blood</i> , 2012 , 120, 3769-3769 | 2.2 | |
| 248 | Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012 , 120, 4234-4234 | 2.2 | |
| 247 | Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. <i>Blood</i> , 2012 , 120, 3742-3742 | 2.2 | |
| 246 | Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. <i>Blood</i> , 2012 , 120, 2797-2797 | 2.2 | |
| 245 | Isolated myeloid sarcoma without bone marrow involvement. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 66-7 | 0.6 | 1 |
| 244 | Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 266-8 | 0.6 | |
| 243 | Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. <i>Cancer Letters</i> , 2011 , 300, 115-21 | 9.9 | 31 |
| 242 | Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011 , 118, 4554-60 | 2.2 | 175 |
| 241 | The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS. <i>Haematologica</i> , 2011 , 96, e45 | 6.6 | 1 |
| 240 | Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 117, 5591-9 | 2.2 | 78 |
| 239 | Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. <i>Haematologica</i> , 2011 , 96, e41-2 | 6.6 | 11 |
| 238 | Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011 , 96, 1390-1 | 6.6 | 16 |
| 237 | Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011 , 96, 1457-61 | 6.6 | 49 |
| 236 | The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). <i>Haematologica</i> , 2011 , 96, e23-4; author reply e25 | 6.6 | 9 |
| 235 | Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. <i>British Journal of Haematology</i> , 2011 , 152, 119-21 | 4.5 | 8 |
| 234 | GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011 , 154, 564-8 | 4.5 | 22 |

| | | | |
|-----|--|------|----|
| 233 | 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. <i>Leukemia</i> , 2011 , 25, 736-7 | 10.7 | 4 |
| 232 | Nilotinib and dasatinib first-line: are we ready for imatinib replacement?. <i>Leukemia Research</i> , 2011 , 35, 1153-5 | 2.7 | |
| 231 | Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011 , 35, 1164-9 | 2.7 | 25 |
| 230 | 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. <i>Leukemia Research</i> , 2011 , 35, 1409-11 | 2.7 | 2 |
| 229 | Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. <i>Leukemia Research</i> , 2011 , 35, e215-6 | 2.7 | 5 |
| 228 | A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia. <i>Annals of Hematology</i> , 2011 , 90, 845-6 | 3 | 6 |
| 227 | Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011 , 86, 523-5 | 7.1 | 4 |
| 226 | Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1372-5 | 1.9 | 3 |
| 225 | Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. <i>BioDrugs</i> , 2011 , 25, 147-57 | 7.9 | 6 |
| 224 | Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 225-34 | 5.4 | 27 |
| 223 | The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 135-43 | 7 | 12 |
| 222 | Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2011 , 35, 159-62 | 2.7 | 33 |
| 221 | Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011 , 35, 504-7 | 2.7 | 11 |
| 220 | Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011 , 35, e69-70 | 2.7 | 2 |
| 219 | Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. <i>Leukemia Research</i> , 2011 , 35, e91-2 | 2.7 | 5 |
| 218 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2075-87 | 4 | 3 |
| 217 | Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011 , 1, 707-717 | | 0 |
| 216 | Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011 , 52, 1143-5.9 | | |

| | | | |
|-----|---|-----|----|
| 215 | Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011021 | 3.2 | 17 |
| 214 | Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011 , 96, 696-702 | 6.6 | 51 |
| 213 | Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. <i>Journal of Clinical Oncology</i> , 2011 , 29, e402-3 | 2.2 | 5 |
| 212 | Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center. <i>Acta Haematologica</i> , 2011 , 126, 1-7 | 2.7 | 5 |
| 211 | Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011 , 118, 2756-2756 | 2.2 | 7 |
| 210 | Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (. <i>Blood</i> , 2011 , 118, 2770-2770 | 2.2 | 1 |
| 209 | International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2011 , 118, 3132-3132 | 2.2 | 3 |
| 208 | Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. <i>Blood</i> , 2011 , 118, 3783-3783 | 2.2 | 2 |
| 207 | Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 118, 453-453 | 2.2 | 1 |
| 206 | MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. <i>Blood</i> , 2011 , 118, 3793-3793 | 2.2 | |
| 205 | Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 2078-2078 | 2.2 | |
| 204 | Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011 , 118, 1682-1682 | 2.2 | 22 |
| 203 | Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011 , 118, 786-786 | 2.2 | |
| 202 | Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. <i>Blood</i> , 2011 , 118, 1026-1026 | 2.2 | 22 |
| 201 | Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. <i>Blood</i> , 2011 , 118, 4445-4445 | 2.2 | |
| 200 | Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. <i>Blood</i> , 2011 , 118, 5157-5157 | 2.2 | |
| 199 | Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. <i>Blood</i> , 2011 , 118, 5172-5172 | 2.2 | |
| 198 | APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. <i>Blood</i> , 2011 , 118, 1686-1686 | 2.2 | |

| | | | |
|-----|--|-----|-----|
| 197 | Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the Gruppo Laziale SMPC Ph Negative \square <i>Blood</i> , 2011 , 118, 3854-3854 | 2.2 | |
| 196 | Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. <i>Blood</i> , 2011 , 118, 2751-2751 | 2.2 | 1 |
| 195 | Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. <i>Blood</i> , 2011 , 118, 4866-4866 | 2.2 | |
| 194 | Reduction of imatinib dose and persistence of complete molecular response after p210 multi-peptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. <i>British Journal of Haematology</i> , 2010 , 150, 240-2 | 4.5 | 2 |
| 193 | Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. <i>Acta Haematologica</i> , 2010 , 124, 46-8 | 2.7 | 17 |
| 192 | Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib. <i>Acta Haematologica</i> , 2010 , 124, 150-2 | 2.7 | 4 |
| 191 | Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 713-21 | 4.1 | 19 |
| 190 | Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010 , 51, 783-8 | 1.9 | 15 |
| 189 | Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. <i>Acta Oncologica</i> , 2010 , 49, 399-400 | 3.2 | 0 |
| 188 | NF-B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 1157-76 | 6.4 | 38 |
| 187 | Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1007-14 | 1.9 | 31 |
| 186 | Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. <i>Hematological Oncology</i> , 2010 , 28, 89-92 ¹⁻³ | | 10 |
| 185 | Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010 , 116, 3171-9 | 2.2 | 249 |
| 184 | Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. <i>Haematologica</i> , 2010 , 95, 853-4 | 6.6 | 37 |
| 183 | The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010 , 95, 1415-9 | 6.6 | 39 |
| 182 | Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010 , 85, 231-5 | 3.8 | 22 |
| 181 | Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. <i>American Journal of Hematology</i> , 2010 , 85, 375-7 | 7.1 | 6 |
| 180 | Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010 , 85, 960-3 | 7.1 | 10 |

| | | | |
|-----|--|-----|----|
| 179 | Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010 , 34, 143-7 | 2.7 | 26 |
| 178 | Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. <i>Leukemia Research</i> , 2010 , 34, 129-34 | 2.7 | 43 |
| 177 | Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment. <i>Leukemia Research</i> , 2010 , 34, e122-4 | 2.7 | 3 |
| 176 | Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. <i>Leukemia Research</i> , 2010 , 34, e224-5 | 2.7 | 4 |
| 175 | Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. <i>Leukemia Research</i> , 2010 , 34, e300-1 | 2.7 | 7 |
| 174 | "Real-life" results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010 , 34, 1472-5 | 2.7 | 41 |
| 173 | Successful Pregnancy In APL Patients Treated According to the AIDA Protocol.. <i>Blood</i> , 2010 , 116, 1037-1037 | 2.7 | 1 |
| 172 | Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL. <i>Blood</i> , 2010 , 116, 15-15 | 2.2 | 3 |
| 171 | Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010 , 116, 2293-2293 | 2.2 | 2 |
| 170 | Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. <i>Blood</i> , 2010 , 116, 3413-3413 | 2.2 | 2 |
| 169 | Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010 , 116, 359-359 | 2.2 | 12 |
| 168 | Comorbidities Indexes In Patients Treated with 5-Azacididine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation. <i>Blood</i> , 2010 , 116, 606-606 | 2.2 | 1 |
| 167 | Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. <i>Blood</i> , 2010 , 116, 4976-4976 | 2.2 | |
| 166 | Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 2270-2270 | 2.2 | |
| 165 | First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, Deep and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2010 , 116, 2720-2720 | 2.2 | |
| 164 | Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia: What Have We Learned Over the Last Twenty Years?.. <i>Blood</i> , 2010 , 116, 3423-3423 | 2.2 | |
| 163 | Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. <i>Blood</i> , 2010 , 116, 2279-2279 | 2.2 | |
| 162 | Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. <i>Blood</i> , 2010 , 116, 3409-3409 | 2.2 | 0 |

| | | | |
|-----|--|------|----|
| 161 | Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. <i>Blood</i> , 2010 , 116, 3077-3077 | 2.2 | |
| 160 | Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). <i>Blood</i> , 2010 , 116, 2927-2927 | 2.2 | |
| 159 | Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. <i>Blood</i> , 2010 , 116, 2281-2281 | 2.2 | |
| 158 | Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study. <i>Blood</i> , 2010 , 116, 4953-4953 | 2.2 | |
| 157 | BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010 , 116, 1230-1230 | 2.2 | 0 |
| 156 | A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. <i>Blood</i> , 2010 , 116, 5065-5065 | 2.2 | |
| 155 | One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥5 years) Ph+ CML Patients [EudraCT Number 2007005102-42, ClinicalTrials.Gov NCT 00858806.. <i>Blood</i> , 2010 , 116, 3412-3412 | 2.2 | |
| 154 | Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. <i>Blood</i> , 2010 , 116, 2273-2273 | 2.2 | |
| 153 | The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. <i>Blood</i> , 2010 , 116, 3399-3399 | 2.2 | |
| 152 | Imatinib In Very Elderly CML Patients: What Can We Achieve?.. <i>Blood</i> , 2010 , 116, 1229-1229 | 2.2 | |
| 151 | Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. <i>Blood</i> , 2010 , 116, 2294-2294 | 2.2 | 1 |
| 150 | Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. <i>Leukemia and Lymphoma</i> , 2009 , 50, 848-50 | 1.9 | 4 |
| 149 | Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009 , 9, 21-8 | 1.1 | 12 |
| 148 | Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. <i>Clinical Cancer Research</i> , 2009 , 15, 1059-63 | 12.9 | 27 |
| 147 | Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009 , 27, 148-53 | 1.3 | 37 |
| 146 | Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient. <i>International Journal of Hematology</i> , 2009 , 89, 720-1 | 2.3 | 5 |
| 145 | Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009 , 90, 486-491 | 2.3 | 1 |
| 144 | Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 1161-3 | 3.5 | 2 |

| | | | |
|-----|---|-----|-----|
| 143 | Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 195-7 | 3.5 | 5 |
| 142 | Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?. <i>Bone Marrow Transplantation</i> , 2009 , 44, 331-2 | 4.4 | 7 |
| 141 | Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. <i>Leukemia Research</i> , 2009 , 33, 200-1 | 2.7 | 2 |
| 140 | Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. <i>Leukemia Research</i> , 2009 , 33, 391-4 | 2.7 | 3 |
| 139 | Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. <i>Leukemia Research</i> , 2009 , 33, 645-8 | 2.7 | 2 |
| 138 | WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?. <i>Leukemia Research</i> , 2009 , 33, e93-4 | 2.7 | 5 |
| 137 | The metabolic consequences of imatinib mesylate: Changes on glucose, lipidic and bone metabolism. <i>Leukemia Research</i> , 2009 , 33, 871-5 | 2.7 | 20 |
| 136 | Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009 , 33, e134-7 | 2.7 | 12 |
| 135 | Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?. <i>Leukemia Research</i> , 2009 , 33, 1450-1 | 2.7 | 1 |
| 134 | Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications. <i>Leukemia and Lymphoma</i> , 2009 , 50, 841-3 | 1.9 | 0 |
| 133 | Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. <i>Leukemia and Lymphoma</i> , 2009 , 50, 387-91 | 1.9 | 40 |
| 132 | Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009 , 50, 114-8 | 1.9 | 6 |
| 131 | The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009 , 94, 205-12 | 6.6 | 54 |
| 130 | Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009 , 113, 3428-34 | 2.2 | 53 |
| 129 | Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 4933-8 | 2.2 | 176 |
| 128 | Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL. <i>Current Drug Targets</i> , 2009 , 10, 530-6 | 3 | 6 |
| 127 | The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2192-2197 | 2.2 | 2 |
| 126 | Chronic Myeloid Leukemia (CML) Patients with Suboptimal Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to Optimal Responders: A GIMEMA CML WORKING PARTY Analysis.. <i>Blood</i> , 2009 , 114, 2196-2196 | 2.2 | 3 |

| | | | |
|-----|--|-----|----|
| 125 | Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2205-2205 | 2.2 | 4 |
| 124 | BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009 , 114, 648-648 | 2.2 | 4 |
| 123 | Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009 , 114, 860-860 | 2.2 | 1 |
| 122 | ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. <i>Blood</i> , 2009 , 114, 4160-4160 | 2.2 | |
| 121 | The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. <i>Blood</i> , 2009 , 114, 1124-1124 | 2.2 | |
| 120 | Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. <i>Blood</i> , 2009 , 114, 1019-1019 | 2.2 | |
| 119 | Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY.. <i>Blood</i> , 2009 , 114, 1118-1118 | 2.2 | 1 |
| 118 | Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. <i>Blood</i> , 2009 , 114, 4271-4271 | 2.2 | |
| 117 | Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. <i>Blood</i> , 2009 , 114, 4545-4545 | 2.2 | |
| 116 | Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. <i>Blood</i> , 2009 , 114, 4985-4985 | 2.2 | |
| 115 | Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. <i>Blood</i> , 2009 , 114, 2763-2763 | 2.2 | 1 |
| 114 | Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. <i>Blood</i> , 2009 , 114, 2211-2211 | 2.2 | |
| 113 | Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. <i>Blood</i> , 2009 , 114, 1777-1777 | 2.2 | |
| 112 | Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria.. <i>Blood</i> , 2009 , 114, 3302-3302 | 2.2 | |
| 111 | Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008 , 143, 681-9 | 4.5 | 50 |
| 110 | Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008 , 49, 994-7 | 1.9 | 8 |
| 109 | Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2328-32 | 1.9 | 8 |
| 108 | Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes. <i>Acta Haematologica</i> , 2008 , 120, 104-7 | 2.7 | 15 |

| | | | |
|-----|--|-----|----|
| 107 | Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008 , 93, 1792-6 | 6.6 | 74 |
| 106 | Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008 , 93, 1918-20 | 6.6 | 15 |
| 105 | Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008 , 26, 106-11 | 2.2 | 40 |
| 104 | Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1292-6 | 1.9 | 8 |
| 103 | Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , 2008 , 93, 770-4 | 6.6 | 49 |
| 102 | Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib. <i>OncoTargets and Therapy</i> , 2008 , 1, 49-58 | 4.4 | 2 |
| 101 | Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. <i>Leukemia Research</i> , 2008 , 32, 177-80 | 2.7 | 14 |
| 100 | Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008 , 32, 255-61 | 2.7 | 11 |
| 99 | Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. <i>Leukemia Research</i> , 2008 , 32, 514-6 | 2.7 | 26 |
| 98 | Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. <i>Leukemia Research</i> , 2008 , 32, 519-20 | 2.7 | 25 |
| 97 | Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2008 , 32, 353-5 | 2.7 | 7 |
| 96 | Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. <i>Leukemia Research</i> , 2008 , 32, 835-6 | 2.7 | 19 |
| 95 | Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008 , 32, 1022-5 | 2.7 | 30 |
| 94 | Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. <i>Leukemia Research</i> , 2008 , 32, 1626-8 | 2.7 | 38 |
| 93 | Pregnancy in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2008 , 32, 1605-7 | 2.7 | 4 |
| 92 | High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008 , 112, 181-181 | 2.2 | 16 |
| 91 | Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). <i>Blood</i> , 2008 , 112, 5237-5237 | 2.2 | 1 |
| 90 | Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. <i>Blood</i> , 2008 , 112, 4288-4288 | 2.2 | |

| | | | |
|----|---|------|----|
| 89 | Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008 , 112, 4253-4253 | 2.2 | |
| 88 | Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. <i>Blood</i> , 2008 , 112, 1949-1949 | | |
| 87 | Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2008 , 112, 4281-4281 | 2.2 | |
| 86 | Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008 , 112, 5097-5097 | 2.2 | |
| 85 | Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008 , 112, 3983-3983 | 2.2 | |
| 84 | Treatment with Imatinib in Very Elderly (> 75 Years) CML Patients.. <i>Blood</i> , 2008 , 112, 1096-1096 | 2.2 | |
| 83 | Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007 , 31, 1770-2 | 2.7 | 49 |
| 82 | Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007 , 21, 79-83 | 10.7 | 88 |
| 81 | Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. <i>Annals of Hematology</i> , 2007 , 86, 295-7 | 3 | 2 |
| 80 | Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007 , 86, 263-70 | 3 | 20 |
| 79 | Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome. <i>Leukemia and Lymphoma</i> , 2007 , 48, 833-4 | 1.9 | 1 |
| 78 | Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. <i>Acta Haematologica</i> , 2007 , 117, 221-5 | 2.7 | 3 |
| 77 | Late relapses in acute promyelocytic leukaemia. <i>Acta Haematologica</i> , 2007 , 117, 106-8 | 2.7 | 14 |
| 76 | Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. <i>Acta Haematologica</i> , 2007 , 118, 162-4 | 2.7 | 7 |
| 75 | Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2007 , 92, 1273-4 | 6.6 | 44 |
| 74 | Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies. <i>Haematologica</i> , 2007 , 92, 666-73 | 6.6 | 21 |
| 73 | In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.. <i>Blood</i> , 2007 , 110, 1934-1934 | 2.2 | 1 |
| 72 | Cocaine abuse may influence the response to imatinib in CML patients. <i>Haematologica</i> , 2007 , 92, e41-2 | 6.6 | 3 |

| | | | |
|----|---|------|----|
| 71 | Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2007 , 110, 4564-4564 | 2.2 | |
| 70 | JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007 , 110, 4652-4652 | 2.2 | |
| 69 | Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response.. <i>Blood</i> , 2007 , 110, 1933-1933 | 2.2 | 1 |
| 68 | Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. <i>Blood</i> , 2007 , 110, 4609-4609 | 2.2 | |
| 67 | Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. <i>Blood</i> , 2007 , 110, 4636-4636 | 2.2 | |
| 66 | Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. <i>Cancer</i> , 2006 , 107, 1008-13 | 6.4 | 26 |
| 65 | Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2006 , 12, 3037-42 | 12.9 | 78 |
| 64 | Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. <i>Annals of Oncology</i> , 2006 , 17, 281-5 | 10.3 | 27 |
| 63 | Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases. <i>Acta Haematologica</i> , 2006 , 116, 211-2 | 2.7 | 1 |
| 62 | Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias. <i>Clinica Chimica Acta</i> , 2006 , 365, 342-5 | 6.2 | 9 |
| 61 | Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. <i>Leukemia</i> , 2006 , 20, 1978-88 | 10.7 | 27 |
| 60 | Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006 , 30, 178-82 | 2.7 | 12 |
| 59 | Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. <i>Leukemia Research</i> , 2006 , 30, 1577-9 | 2.7 | 28 |
| 58 | Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2006 , 108, 1979-1979 | 2.2 | 4 |
| 57 | Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell'Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2006 , 108, 4776-4776 | 2.2 | |
| 56 | Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. <i>Blood</i> , 2006 , 108, 3595-3595 | 2.2 | |
| 55 | Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.. <i>Blood</i> , 2006 , 108, 2156-2156 | 2.2 | |
| 54 | Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 3320-3320 | 2.2 | |

| | | | |
|----|---|------|----|
| 53 | Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006 , 108, 2158-2158 | 2.2 | |
| 52 | Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. <i>Blood</i> , 2006 , 108, 2667-2667 | 2.2 | 1 |
| 51 | Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006 , 91, 1566-8 | 6.6 | 70 |
| 50 | Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005 , 29, 33-9 | 2.7 | 8 |
| 49 | Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005 , 29, 287-91 | 2.7 | 19 |
| 48 | Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005 , 29, 749-54 | 2.7 | 19 |
| 47 | BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005 , 36, 83-4 | 4.4 | 4 |
| 46 | Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. <i>Leukemia</i> , 2005 , 19, 287-9 | 10.7 | 2 |
| 45 | Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005 , 74, 89-90 | 3.8 | 39 |
| 44 | Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005 , 74, 121-3 | 3.8 | 53 |
| 43 | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?. <i>European Journal of Haematology</i> , 2005 , 75, 89-90 | 3.8 | 6 |
| 42 | Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. <i>European Journal of Haematology</i> , 2005 , 75, 396-400 | 3.8 | 7 |
| 41 | Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2005 , 106, 1098-1098 | 2.2 | |
| 40 | Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005 , 106, 885-885 | 2.2 | |
| 39 | Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005 , 106, 887-887 ^{2.2} | | |
| 38 | Acute myeloid leukemia secondary to a myelodysplastic syndrome with t(3;3) (q21;q26) in an HIV patient treated with chemotherapy and highly active antiretroviral therapy. <i>Acta Haematologica</i> , 2004 , 111, 160-2 | 2.7 | 8 |
| 37 | Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004 , 18, 182 | 10.7 | 15 |
| 36 | Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. <i>Leukemia</i> , 2004 , 18, 361-2 | 10.7 | 17 |

| | | | |
|----|---|------|-----|
| 35 | Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2004 , 73, 304-6 | 3.8 | 5 |
| 34 | Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. <i>Leukemia Research</i> , 2004 , 28, 1165-9 | 2.7 | 83 |
| 33 | Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004 , 104, 1995-9 | 2.2 | 203 |
| 32 | Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. <i>Blood</i> , 2004 , 104, 4693-4693 | 2.2 | 1 |
| 31 | Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. <i>Haematologica</i> , 2004 , 89, 29-33 | 6.6 | 27 |
| 30 | Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. <i>Haematologica</i> , 2004 , 89, ECR11 | 6.6 | 6 |
| 29 | Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2004 , 89, 615-7 | 6.6 | 12 |
| 28 | Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004 , 89, 866-8 | 6.6 | 23 |
| 27 | Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia. <i>Haematologica</i> , 2004 , 89, ECR20 | 6.6 | |
| 26 | Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation. <i>European Journal of Haematology</i> , 2003 , 70, 190-2 | 3.8 | 20 |
| 25 | Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. <i>British Journal of Haematology</i> , 2003 , 120, 266-70 | 4.5 | 42 |
| 24 | Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003 , 17, 925-30 | 10.7 | 28 |
| 23 | Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. <i>Leukemia</i> , 2003 , 17, 919-24 | 10.7 | 50 |
| 22 | The importance of molecular monitoring in acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003 , 16, 503-20 | 4.2 | 21 |
| 21 | Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003 , 16, 653-70 | 4.2 | 4 |
| 20 | Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003 , 102, 1035-41 | 2.2 | 70 |
| 19 | Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. <i>European Journal of Haematology</i> , 2002 , 68, 1-3 | 3.8 | 13 |
| 18 | Conservative treatment for patients over 80 years with acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2002 , 71, 256-9 | 7.1 | 10 |

| | | | |
|----|--|------|-----|
| 17 | Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002 , 116, 576-81 | 4.5 | 71 |
| 16 | Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. <i>British Journal of Haematology</i> , 2002 , 116, 299-307 | 4.5 | 20 |
| 15 | Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?. <i>British Journal of Haematology</i> , 2002 , 118, 438-41 | 4.5 | 20 |
| 14 | Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. <i>Leukemia</i> , 2002 , 16, 1293-301 | 10.7 | 27 |
| 13 | Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. <i>Leukemia</i> , 2002 , 16, 2185-9 | 10.7 | 164 |
| 12 | Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated 'sanctuary'?. <i>Leukemia</i> , 2002 , 16, 1127-30 | 10.7 | 28 |
| 11 | Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002 , 99, 822-4 | 2.2 | 110 |
| 10 | AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. <i>Haematologica</i> , 2002 , 87, ELT12 | 6.6 | 6 |
| 9 | Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. <i>British Journal of Haematology</i> , 2002 , 116, 299-307 | 4.5 | 9 |
| 8 | Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. <i>Annals of Hematology</i> , 2001 , 80, 614-6 | 3 | 13 |
| 7 | Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. <i>British Journal of Haematology</i> , 2001 , 113, 136-42 | 4.5 | 15 |
| 6 | Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction. <i>Leukemia and Lymphoma</i> , 2000 , 36, 539-41 | 1.9 | 1 |
| 5 | Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy. <i>Acta Haematologica</i> , 2000 , 104, 34-7 | 2.7 | 13 |
| 4 | Flt3LP3 induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999 , 106, 133-41 | 4.5 | 20 |
| 3 | Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999 , 13, 514-7 | 10.7 | 17 |
| 2 | The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. <i>Annals of Oncology</i> , 1997 , 8, 1273-5 | 10.3 | 20 |
| 1 | Acute promyelocytic leukemia: pathophysiology and clinical results update 131-140 | | |